



*Schedule  
 at a Glance*

All times listed in Eastern Daylight Time [EDT] • Schedule is subject to change

**Fellows in Training (FIT) at Education Exchange** APRIL 28, 9:00 AM–5:30 PM • WINDERMERE W

Welcome Remarks	9:00 AM
Muscle Strength Exam	9:10 AM
Regional Shoulder Exam	9:10 AM
Rheumatology Medications <i>(Focus on Adverse Events, Patient Counseling, and Toxicity Monitoring)</i>	9:10 AM
Axial Spondyloarthritis Exam	9:10 AM
Getting Involved with ACR	11:00 AM
Building Successful Mentor-Mentee Relationships	11:30 AM
Lunch	12:30 PM
The Great Debates by Rheumatology Fellows	1:30 PM
Preparing for Rheumatology Boards	3:00 PM
Roundtable Discussions	4:00 PM
Closing Remarks	5:25 PM
Adjourn	5:30 PM

**Coding Guidelines Workshop—Updates & Impacts** APRIL 28, 9:00 AM–5:00 PM • WINDERMERE Y

Welcome	9:00 AM
Review of Key 2023 E/M Code Changes	9:10 AM
Break	10:00 AM
Taking a Closer Look at Billing Time vs. MDM	10:15 AM
Split/Shared Changes & Incident-to Rule	11:00 AM
Lunch	12:00 PM
Deep Dive into Rheumatology Procedures	1:00 PM
Drug Wastage Billing and Coverage Guidelines	2:00 PM
Break	3:00 PM
Outpatient Audits in 2023	3:15 PM
Roundtable Discussions	4:00 PM
Adjourn	5:00 PM

**Division Directors Conference** APRIL 28, 9:00 AM–12:30 PM • WINDERMERE Z

Welcome Remarks	9:00 AM
Engaging in Philanthropy in the Rheumatology Division	9:05 AM
Successful Strategies for Recruitment: Contracts and Compensation	9:45 AM
Improving Recruitment of URM Students, Fellows and Faculty	11:00 AM
Update on Division Directors Committee	12:15 PM
Adjourn	12:30 PM



**Joint Division Directors and Educators Conference** APRIL 28, 1:30–6:00 PM • WINDERMERE Z

Welcome Remarks: Joint Session of Educators and Division Directors	1:30 PM
ACR Advocacy Update	1:35 PM
ACGME Update	2:00 PM
International Medical Graduates (IMGs)–Challenges Represented Along Various Pathways	2:30 PM
How Division Directors Can Support Clinician Educators	4:00 PM
Building Stronger Alliances Between Academic Adult and Pediatric Rheumatology Programs	4:45 PM
Update from the Rheumatology Research Foundation	5:45 PM
Closing Remarks	5:55 PM
Adjourn	6:00 PM

**Educators Conference** APRIL 29, 9:00 AM–6:00 PM • WINDERMERE Z

Nuts and Bolts: How to Succeed as a Rheumatology Program Director	9:00 AM
Update from Committee on Rheumatology Training and Workforce Issues (COTW)	10:00 AM
Education and Wellness Inspirations [Teaching Pearls]	11:00 AM
Lunch	12:30 PM
Keynote: 2022 Distinguished Fellowship Program Director Award	1:30 PM
ACR Resources for Educators and Trainees	2:15 PM
Introduction: Concurrent Workshops– <i>all workshops are in Celebration 9-12</i>	4:00 PM
CONCURRENT WORKSHOP: Clinician Educators – Navigating Career Pathways	4:05 PM
CONCURRENT WORKSHOP: No Rheum for Error: Teaching Fellows to Consider Cognitive Errors	4:05 PM
CONCURRENT WORKSHOP: Incorporating Quality Improvement into Fellowship Teaching	4:05 PM
CONCURRENT WORKSHOP: Online Resources for Rheumatology Education	4:05 PM
Adjourn	6:00 PM

**ACR/ARP Access in Rheumatology Meeting** APRIL 29, 9:00 AM–12:00 PM • WINDERMERE W

Welcome Remarks	9:00 AM
Thriving, Not Just Surviving–Keeping Your Rheumatology Practice Solvent	9:10 AM
Optimizing Patient Access to Treatment	10:25 AM
Closing Remarks	11:25 AM
Roundtable Discussions	11:30 AM
Adjourn	12:00 PM



<b>State-of-the-Art Clinical Symposium (SOTA) APRIL 29–30 • REGENCY O-R</b>	
<b>April 29, 9:00 AM–7:30 PM</b>	
New Drugs on the Block (Indications and Safety Concerns)	9:00 AM
Challenging Cases Small Vessel	10:00 AM
Break	10:30 AM
Challenging Cases Large Vessel	11:00 AM
Challenging Neuropsychiatric Lupus	11:40 AM
Lunch	12:30 PM
Dermatomyositis	1:30 PM
Myositis-ILD	2:00 PM
Lung Transplant and Rheumatic Diseases	2:30 PM
Kawasaki Disease Guidelines	3:00 PM
Break	3:30 PM
Pediatrics Year in Review	4:00 PM
Hypophosphatasia	4:40 PM
Cocktails and Cases— <i>located in Regency S-V</i>	5:20 PM
Adjourn	6:20 PM
Industry Session—Addressing Radiographic Progression in Psoriatic Arthritis— <i>Celebration 3-4—No CME</i>	6:30 PM
<b>April 30, 8:00 AM–3:00 PM</b>	
Industry Session—Review of an Approved Janus Kinase Inhibitor in Patients With Moderate to Severe Rheumatoid Arthritis— <i>Celebration 3-4—No CME</i>	8:00 AM
Global Rheumatology Health Issues or Racial Disparities	9:00 AM
ACR Advocacy Update: Help Us, Help You	9:30 AM
Inflammatory Eye Disease	10:00 AM
Biologics Management of Psoriasis	11:00 AM
Pericarditis Management	11:30 AM
Challenging Cases of Lupus Nephritis	12:00 PM
Lunch	12:30 PM
Updates on the Diagnosis and Treatment of Spondyloarthritis	1:30 PM
Applications of Ultrasound in Current Rheumatology Practice	2:00 PM
Gout Updates	2:30 PM
Adjourn	3:00 PM



## Industry Sessions at SOTA **CELEBRATION 3-4**

We have two opportunities for you to attend our industry partners' education offering. Please join us in Celebration 3-4 on Saturday following the educational sessions and on Sunday prior to the start!

**Saturday, April 29, 6:30-7:30 PM**

### **Addressing Radiographic Progression in Psoriatic Arthritis**

**Sponsored by Eli Lilly & Company – Non-CME**

#### **Learning Objectives:**

- Provide an overview of Radiographic Damage in PsA
- Highlight Impact of Radiographic Damage on the Patient
- Discuss the impact of delayed treatment in the Context of Radiographic Progression

#### **Session Description:**

Radiologic damage in PsA is directly associated with worse outcomes, including quality of life and function. DMARDs currently available in clinical practice need to address this, and HCPs need to be aware of and how to assess radiologic damage as they care for their patients.

#### **Agenda:**

1. Overview of Radiographic Progression in PsA
2. Impact of Radiographic Progression on the Patient
3. Treatments in the Context of Radiographic Progression
4. Summary and Q&A

**Sunday, April 30, 8:00-9:00 AM**

### **Review of an Approved Janus Kinase Inhibitor in Patients With Moderate to Severe Rheumatoid Arthritis**

**Sponsored by Pfizer – Non-CME**

#### **Learning Objectives:**

Understand the efficacy and safety profile of a prescription Janus kinase inhibitor (JAKi) treatment option, approved for the treatment of patients with moderate to severe rheumatoid arthritis (RA)

#### **Session Description:**

- Create a wholistic understanding of the benefit: risk profile for an approved, prescription JAKi as an approach for treating moderate to severe RA
- Review the clinical efficacy and safety profile for Rx JAKi to help HCPs determine if this prescription treatment option is an appropriate option for their patients with moderate to severe RA.

#### **Agenda:**

Review clinical efficacy and safety data for a prescription JAKi approved for the treatment of patients with moderate to severe RA